The company focuses on developing a proprietary genome editing platform based on CRISPR/Cas9 technology, which uses a protein-RNA complex to recognize and repair DNA sequences. Editas Medicine has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies. The company's goal is to discover, develop, manufacture, and commercialize transformative, precision genomic medicines for a broad class of diseases. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, with a growing site in Boulder, Colorado. Editas Medicine is a vibrant company with a distinct culture and expert team of "Editors" who aspire to help patients around the world.